FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Can J Vet Res / Comparison of 2 endothelin-receptor antagonists on in vitro ...
Canadian journal of veterinary research = Revue canadienne de recherche veterinaire2006; 70(3); 197-205;

Comparison of 2 endothelin-receptor antagonists on in vitro responses of equine palmar digital arterial and venous rings to endothelin-1.

Abstract: The goals of this study were to determine the concentration-response (C-R) relationship of endothelin-1 (ET-1), compare 2 ET-receptor antagonists and determine the antagonist concentrations that block the vasomotor effects of ET-1, and compare the effectiveness of ET-1 and previously studied vasoconstrictors in equine palmar digital arterial and venous rings in vitro. Vessel rings from 8 nonlaminitic horses were placed in Tyrode's solution, 1 side fixed to the floor of an organ bath and the other side fixed to a force-displacement transducer. Two separate studies were conducted: (I) incubation with a single ET-receptor antagonist (PD142893 or PD145065 at a concentration of 10(-7), 10(-6), or 10(-5) M), followed by determination of an ET-1 C-R curve (using concentrations of 10(-10) to 10(-6) M) for medial vessel rings; and (II) comparison of ET-1 with norepinephrine and histamine (10(-10) to 10(-6) M) and comparison of contractile responses of medial and lateral vessel rings. In study I, ET-1 administration caused pronounced and sustained concentration-dependent contraction of vessel rings; these contractile responses were decreased by 10(-5) M PD142893 and were completely blocked by 10(-5) M PD145065. Venous rings had greater apparent maximum contraction in response to ET-1 than arterial rings. In study II, the relative sensitivity of norepinephrine was found to be equivalent to that of ET-1, whereas that of histamine was lower. No significant differences were observed between responses of medial versus lateral vessel rings. Thus, ET-1 is a potent vasoconstrictor of equine palmar digital arteries and veins, and the ET-receptor antagonist PD145065 is more effective than PD142893 in inhibiting these contractile effects in vitro. (Traduit par Docteur Serge Messier)
Get Full Text
Publication Date: 2006-07-21 PubMed ID: 16850942PubMed Central: PMC1477928
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Comparative Study
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This study investigates the responses of horse vascular tissue to endothelin-1, a potent vasoconstrictor, and compares the effects of two different types of antagonist drugs on these responses. Endothelin-1 was found to cause intense and prolonged contraction of vascular tissue, which was lessened by the drug PD142893 and completely blocked by the drug PD145065.

Research Objective and Methods

  • The researchers sought to establish the relationship between the concentration of endothelin-1 (ET-1), a potent vasoconstrictor, and its effect on palmar digital arterial and venous rings in horses. They aimed to compare the effectiveness of two ET-receptor antagonists (PD142893 and PD145065) in blocking the vasomotor effects of ET-1.
  • The research involved the use of vessel rings from eight nonlaminitic horses. These were placed in Tyrode’s solution, with one side fixed to an organ bath base and the other attached to a force-displacement transducer. This setup allowed the researchers to monitor and measure the contraction of the vessel rings in response to various substances.

Twin Research Studies

  • In the first part of this study, the research evaluated the effects of a single dose of an ET-receptor antagonist followed by ET-1 on medial vessel rings. Different concentrations of the antagonists (PD142893 or PD145065) were tested. It was observed that ET-1 caused pronounced and long-lasting concentration-dependent contractions of the vessel rings. These contractions were reduced at 10(-5) M concentration of PD142893 and were completely blocked at the same concentration of PD145065.
  • The second part of the study compared the effects of ET-1, norepinephrine, and histamine on medial and lateral vessel rings. It found that the relative sensitivity of norepinephrine was similar to that of ET-1, whereas histamine’s was lower. There were no significant differences observed between the responses of medial versus lateral vessel rings.

Research Findings and Implications

  • The research established that ET-1 is a powerful vasoconstrictor of equine palmar digital arteries and veins. It also determined that the ET-receptor antagonist PD145065 is more effective than PD142893 in blocking these contractile effects in a laboratory setting. The greater apparent maximum contraction responses to ET-1 in venous rings than in arterial rings was another notable finding.
  • The study’s results could potentially inform future research in developing more effective ET-receptor antagonists, which could then be utilized in the management or treatment of diseases related to vascular tissue contraction in horses.

Cite This Article

APA
Stokes AM, Venugopal CS, Hosgood G, Eades SC, Moore RM. (2006). Comparison of 2 endothelin-receptor antagonists on in vitro responses of equine palmar digital arterial and venous rings to endothelin-1. Can J Vet Res, 70(3), 197-205.

Publication

Canadian journal of veterinary research = Revue canadienne de recherche veterinaire
ISSN: 0830-9000
NlmUniqueID: 8607793
Country: Canada
Language: English
Volume: 70
Issue: 3
Pages: 197-205

Researcher Affiliations

Stokes, Ashley M
  • Equine Health Studies Program, Department of Veterinary Clinical Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge 70803-8410, USA. astokes@lsu.edu
Venugopal, Changaram S
    Hosgood, Giselle
      Eades, Susan C
        Moore, Rustin M

          MeSH Terms

          • Animals
          • Arteries / drug effects
          • Arteries / physiology
          • Dose-Response Relationship, Drug
          • Endothelin Receptor Antagonists
          • Endothelin-1 / antagonists & inhibitors
          • Endothelin-1 / pharmacology
          • Horses / physiology
          • In Vitro Techniques
          • Muscle, Smooth, Vascular / drug effects
          • Muscle, Smooth, Vascular / physiology
          • Oligopeptides
          • Toes / blood supply
          • Veins / drug effects
          • Veins / physiology

          References

          This article includes 39 references
          1. Yanagisawa M, Kurihara H, Kimura S, Goto K, Masaki T. A novel peptide vasoconstrictor, endothelin, is produced by vascular endothelium and modulates smooth muscle Ca2+ channels.. J Hypertens Suppl 1988 Dec;6(4):S188-91.
            pubmed: 2853725doi: 10.1097/00004872-198812040-00056google scholar: lookup
          2. Inoue A, Yanagisawa M, Kimura S, Kasuya Y, Miyauchi T, Goto K, Masaki T. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes.. Proc Natl Acad Sci U S A 1989 Apr;86(8):2863-7.
            pmc: PMC287019pubmed: 2649896doi: 10.1073/pnas.86.8.2863google scholar: lookup
          3. Resink TJ, Hahn AW, Scott-Burden T, Powell J, Weber E, Bühler FR. Inducible endothelin mRNA expression and peptide secretion in cultured human vascular smooth muscle cells.. Biochem Biophys Res Commun 1990 May 16;168(3):1303-10.
            pubmed: 2161221doi: 10.1016/0006-291x(90)91171-ngoogle scholar: lookup
          4. Gwathmey JK, Paige JA. Endothelin and vasoactive peptides: new cardiovascular mediators.. J Vet Pharmacol Ther 1994 Dec;17(6):420-5.
            pubmed: 7707486doi: 10.1111/j.1365-2885.1994.tb00272.xgoogle scholar: lookup
          5. Rubanyi GM, Polokoff MA. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology.. Pharmacol Rev 1994 Sep;46(3):325-415.
            pubmed: 7831383
          6. MacLean MR, Randall MD, Hiley CR. Effects of moderate hypoxia, hypercapnia and acidosis on haemodynamic changes induced by endothelin-1 in the pithed rat.. Br J Pharmacol 1989 Nov;98(3):1055-65.
            pmc: PMC1854766pubmed: 2511990doi: 10.1111/j.1476-5381.1989.tb14638.xgoogle scholar: lookup
          7. Cocks TM, Faulkner NL, Sudhir K, Angus J. Reactivity of endothelin-1 on human and canine large veins compared with large arteries in vitro.. Eur J Pharmacol 1989 Nov 14;171(1):17-24.
            pubmed: 2693123doi: 10.1016/0014-2999(89)90425-1google scholar: lookup
          8. Venugopal CS, Holmes EP, Koch CE, Curtis LA, Holm AS, Moore RM. In vitro pharmacologic effect of two endothelin-1 antagonists on equine colonic arteries and veins.. Am J Vet Res 2001 Feb;62(2):154-9.
            pubmed: 11212019doi: 10.2460/ajvr.2001.62.154google scholar: lookup
          9. Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM, Burnett JC Jr. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis.. N Engl J Med 1991 Oct 3;325(14):997-1001.
            pubmed: 1886637doi: 10.1056/nejm199110033251404google scholar: lookup
          10. Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure.. Circulation 1992 Feb;85(2):504-9.
            pubmed: 1735147doi: 10.1161/01.cir.85.2.504google scholar: lookup
          11. Nakamura T, Kasai K, Sekiguchi Y, Banba N, Takahashi K, Emoto T, Hattori Y, Shimoda S. Elevation of plasma endothelin concentrations during endotoxin shock in dogs.. Eur J Pharmacol 1991 Dec 3;205(3):277-82.
            pubmed: 1667911doi: 10.1016/0014-2999(91)90910-igoogle scholar: lookup
          12. Ramaswamy CM, Eades SC, Venugopal CS, Hosgood GL, Garza F, Barker SA, Moore RM. Plasma concentrations of endothelin-like immunoreactivity in healthy horses and horses with naturally acquired gastrointestinal tract disorders.. Am J Vet Res 2002 Mar;63(3):454-8.
            pubmed: 11911584doi: 10.2460/ajvr.2002.63.454google scholar: lookup
          13. Moore JN, Allen D Jr, Clark ES. Pathophysiology of acute laminitis.. Vet Clin North Am Equine Pract 1989 Apr;5(1):67-72.
            pubmed: 2650832doi: 10.1016/s0749-0739(17)30604-1google scholar: lookup
          14. Allen D Jr, Clark ES, Moore JN, Prasse KW. Evaluation of equine digital Starling forces and hemodynamics during early laminitis.. Am J Vet Res 1990 Dec;51(12):1930-4.
            pubmed: 2085218
          15. Hood DM, Amoss MS, Hightower D. Equine laminitis. I: Radioisotopic analysis of the hemodynamics of the foot during the acute disease.. J Equine Med Surg 1978;2:439–444.
          16. Baxter GM. Equine laminitis caused by distal displacement of the distal phalanx: 12 cases (1976-1985).. J Am Vet Med Assoc 1986 Aug 1;189(3):326-9.
            pubmed: 3744996
          17. Garner HE, Coffman JR, Hahn AW, Hutcheson DP, Tumbleson ME. Equine laminitis of alimentary origin: an experimental model.. Am J Vet Res 1975 Apr;36(4 Pt.1):441-4.
            pubmed: 1124880
          18. Garner HE, Hahn AW, Salem C, Coffman JR, Hutcheson DP, Johnson JH. Cardiac output, left ventricular ejection rate, plasma volume, and heart rate changes in equine laminitis-hypertension.. Am J Vet Res 1977 Jun;38(6):725-9.
            pubmed: 879570
          19. Garner HE, Coffman JR, Hahn AW, Ackerman N, Johnson JH. Equine laminitis and associated hypertension: a review.. J Am Vet Med Assoc 1975 Jan 1;166(1):56-7.
            pubmed: 1089098
          20. Baxter GM. Alterations of endothelium-dependent digital vascular responses in horses given low-dose endotoxin.. Vet Surg 1995 Mar-Apr;24(2):87-96.
            pubmed: 7778262doi: 10.1111/j.1532-950x.1995.tb01301.xgoogle scholar: lookup
          21. Zerpa H, Vega F, Vasquez J, Ascanio E, Campos G, Sogbe E, Romero E, Ascanio M, García H. Effect of acute sublethal endotoxaemia on in vitro digital vascular reactivity in horses.. J Vet Med A Physiol Pathol Clin Med 2005 Mar;52(2):67-73.
            pubmed: 15737174doi: 10.1111/j.1439-0442.2004.00684.xgoogle scholar: lookup
          22. Moore RM, Sedrish SA, Holmes EP, Koch CE, Venugopal CS. Role of endothelium and nitric oxide in modulating in vitro responses of colonic arterial and venous rings to vasodilatory neuropeptides in horses.. Can J Vet Res 2005 Apr;69(2):116-22.
            pmc: PMC1142178pubmed: 15971675
          23. Baxter GM, Laskey RE, Tackett RL, Moore JN, Allen D. In vitro reactivity of digital arteries and veins to vasoconstrictive mediators in healthy horses and in horses with early laminitis.. Am J Vet Res 1989 Apr;50(4):508-17.
            pubmed: 2712417
          24. Baxter GM, Tackett RL, Moore JN. Reactivity of equine palmar digital arteries and veins to vasodilating agents.. Vet Surg 1989 May-Jun;18(3):221-6.
            pubmed: 2773284doi: 10.1111/j.1532-950x.1989.tb01075.xgoogle scholar: lookup
          25. O'Malley NA, Venugopalan CS, Crawford MP. Contractile responses to histamine of isolated pulmonary artery strips from healthy and heartworm-infected dogs.. Am J Vet Res 1985 Jul;46(7):1463-7.
            pubmed: 4026028
          26. Venugopalan CS, Flory W, Tucker TA, Hebert CD, Strain GM. Assessment of smooth muscle function in Sesbania drummondii toxicosis in Gallus domesticus.. Am J Vet Res 1984 Apr;45(4):764-8.
            pubmed: 6731992
          27. Arunlakshana O, Schild HO. Some quantitative uses of drug antagonists. 1958.. Br J Pharmacol 1997 Feb;120(4 Suppl):151-61; discussion 148-50.
            pmc: PMC3224288pubmed: 9142403doi: 10.1111/j.1476-5381.1997.tb06793.xgoogle scholar: lookup
          28. Schroeder RL, Keiser JA, Cheng XM, Haleen SJ. PD 142893, SB 209670, and BQ 788 selectively antagonize vascular endothelial versus vascular smooth muscle ET(B)-receptor activity in the rat.. J Cardiovasc Pharmacol 1998 Dec;32(6):935-43.
            pubmed: 9869499doi: 10.1097/00005344-199812000-00010google scholar: lookup
          29. Doherty AM, Cody WL, He JX, DePue PL, Cheng XM, Welch KM, Flynn MA, Reynolds EE, LaDouceur DM, Davis LS. In vitro and in vivo studies with a series of hexapeptide endothelin antagonists.. J Cardiovasc Pharmacol 1993;22 Suppl 8:S98-102.
            pubmed: 7510009doi: 10.1097/00005344-199322008-00027google scholar: lookup
          30. Katwa LC, Johnson PJ, Ganjam VK, Kreeger JM, Messer NT. Expression of endothelin in equine laminitis.. Equine Vet J 1999 May;31(3):243-7.
            pubmed: 10402139doi: 10.1111/j.2042-3306.1999.tb03180.xgoogle scholar: lookup
          31. Benamou AE, Art T, Marlin DJ, Roberts CA, Lekeux P. Variations in systemic and pulmonary endothelin-1 in horses with recurrent airway obstruction (heaves).. Pulm Pharmacol Ther 1998 Apr-Jun;11(2-3):231-5.
            pubmed: 9918762doi: 10.1006/pupt.1998.0144google scholar: lookup
          32. Wagner OF, Christ G, Wojta J, Vierhapper H, Parzer S, Nowotny PJ, Schneider B, Waldhäusl W, Binder BR. Polar secretion of endothelin-1 by cultured endothelial cells.. J Biol Chem 1992 Aug 15;267(23):16066-8.
            pubmed: 1644793
          33. Venugopalan CS, Moore RM, Holmes EP, Sedrish SA, Koch CE. Biphasic responses of equine colonic vessel rings to vasoactive inflammatory mediators.. J Auton Pharmacol 1998 Aug;18(4):231-7.
            pubmed: 9788293doi: 10.1046/j.1365-2680.1998.18488.xgoogle scholar: lookup
          34. Venugopalan CS, Moore RM, Holmes EP, Sedrish SA. Role of endothelium and nitric oxide in the response of equine colonic arterial rings to vasoconstrictor agents.. Vet Surg 1997 May-Jun;26(3):182-8.
            pubmed: 9150555doi: 10.1111/j.1532-950x.1997.tb01482.xgoogle scholar: lookup
          35. Eyre P, Elmes PJ, Strickland S. Corticosteroid-potentiated vascular responses of the equine digit: a possible pharmacologic basis for laminitis.. Am J Vet Res 1979 Jan;40(1):135-8.
            pubmed: 453675
          36. Weiss DJ, Evanson OA, McClenahan D, Fagliari JJ, Jenkins K. Evaluation of platelet activation and platelet-neutrophil aggregates in ponies with alimentary laminitis.. Am J Vet Res 1997 Dec;58(12):1376-80.
            pubmed: 9401684
          37. Weiss DJ, Trent AM, Johnston G. Prothrombotic events in the prodromal stages of acute laminitis in horses.. Am J Vet Res 1995 Aug;56(8):986-91.
            pubmed: 8533989
          38. Sanz MJ, Johnston B, Issekutz A, Kubes P. Endothelin-1 causes P-selectin-dependent leukocyte rolling and adhesion within rat mesenteric microvessels.. Am J Physiol 1999 Nov;277(5):H1823-30.
            pubmed: 10564136doi: 10.1152/ajpheart.1999.277.5.h1823google scholar: lookup
          39. Jagroop IA, Mikhailidis DP. Effect of endothelin-1 on human platelet shape change: reversal of activation by naftidrofuryl.. Platelets 2000 Aug;11(5):272-7.
            pubmed: 11030461doi: 10.1080/09537100050129288google scholar: lookup

          Citations

          This article has been cited 2 times.
          1. Menzies-Gow NJ, Wray H, Bailey SR, Harris PA, Elliott J. The effect of tumour necrosis factor-α and insulin on equine digital blood vessel function in vitro. Inflamm Res 2014 Aug;63(8):637-47.
            doi: 10.1007/s00011-014-0736-2pubmed: 24764104google scholar: lookup
          2. Gauff FC, Patan-Zugaj B, Licka TF. Effect of short-term hyperinsulinemia on the localization and expression of endothelin receptors A and B in lamellar tissue of the forelimbs of horses. Am J Vet Res 2014 Apr;75(4):367-74.
            doi: 10.2460/ajvr.75.4.367pubmed: 24669922google scholar: lookup
          Subscribe to our newsletter
          Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.